- Who We Are
- Updates & News
- Standards
- Software Tools
- Network Studies
- Community Forums
- Education
- New To OHDSI?
- Community Calls
- Past Events
- 2023 APAC Symposium
- 2023 Europe Symposium
- 2023 SOS Challenge
- 2023 DevCon
- 2023 Phenotype Phebruary
- 2022 Global Symposium
- 2022 APAC Symposium
- 2022 European Symposium
- 2022 DevCon
- 2021 Global Symposium
- 2021 APAC Symposium
- 2020 Global Symposium
- 2020 APAC Symposium
- Past OHDSI Events
- Asia-Pacific (APAC) Community
- Weekly Community Calls
- Workgroups
- OHDSI Annual Report: Our Journey
- Community Dashboards
- This Week In OHDSI
- OHDSI Publications
- Support & Sponsorship
- 2023 Global Symposium
- Github
- YouTube
- Newsletters
Welcome To OHDSI
OHDSI is a global community uniquely positioned to make a critical difference in healthcare.
How does Observational Health Data Sciences and Informatics — OHDSI, pronounced "Odyssey" — fulfill its mission of empowering a community to collaboratively generate the real-world evidence
that promotes better health decisions and better care?
3,000+
Researchers
920 Million
Patient Records
Open-Source
Analytics
Community
Research
We are a global community that includes more than 3,000 researchers from more than 80 nations across six continents.
Through the OMOP CDM, we have access to 920 million de-identified patient records — nearly 12% of the world's population
We use systematic research methods and open-source tools to generate reliable, robust real-world evidence.
We believe in the core tenets of open science and collaboration.
We can make a difference by working together!
OHDSI developed and uses the OMOP Common Data Model, an open-source platform for observational research. This data model allows for the standardization of health data from various sources, allowing the analysis of large datasets from multiple sources in a consistent and reproducible manner. OHDSI has also produced a suite of open-source software packages that enables the community to translate that data into reliable evidence.
• more than 500 peer-review studies published in scientific literature
• cited by European Medicines Agency in decision to re-authorize Astra-Zeneca’s COVID-19 vaccine
• collaborating with the U.S. Food and Drug Administration to conduct safety and effectiveness surveillance of biologic products, including vaccines
• showed that most popular antihypertensive drug wasn't most effective
Hear From The OHDSI Community
How Can You Get Involved?
SOS Challenge Focuses On Teaching Process Of & Executing Four Network Studies In 9 Weeks
Collaborator Showcase:
Azza Shoaibi
